Nicotine and Parkinson's disease: Implications for therapy
Identifieur interne : 002734 ( Main/Curation ); précédent : 002733; suivant : 002735Nicotine and Parkinson's disease: Implications for therapy
Auteurs : Maryka Quik [États-Unis] ; Kathryn O'Leary [États-Unis] ; Caroline M. Tanner [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2008-09.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Tabagisme.
English descriptors
- KwdEn :
- Animals, Antiparkinson Agents (therapeutic use), Dyskinesia, Humans, Levodopa, L‐dopa, Nervous system diseases, Nicotine, Nicotine (therapeutic use), Nicotinic receptor, Parkinson Disease (drug therapy), Parkinson Disease (epidemiology), Parkinson disease, Tobacco smoking, Treatment, dyskinesias, neuroprotection, nicotinic receptors, smoking, striatum.
- MESH :
- chemical , therapeutic use : Antiparkinson Agents, Nicotine.
- drug therapy : Parkinson Disease.
- epidemiology : Parkinson Disease.
- Animals, Humans.
Abstract
Accumulating evidence suggests that nicotine, a drug that stimulates nicotinic acetylcholine receptors, may be of therapeutic value in Parkinson's disease. Beneficial effects may be several‐fold. One of these is a protective action against nigrostriatal damage. This possibility stems from the results of epidemiological studies that consistently demonstrate an inverse correlation between tobacco use and Parkinson's disease. This reduced incidence of Parkinson's disease has been attributed to the nicotine in tobacco products, at least in part, based on experimental work showing a protective effect of nicotine against toxic insults. Second, several studies suggest a symptomatic effect of nicotine in Parkinson's disease, although effects are small and somewhat variable. Third, recent data in nonhuman primates show that nicotine attenuates levodopa‐induced dyskinesias, a debilitating side effect that develops in the majority of patients on levodopa therapy. Collectively, these observations suggest that nicotine or CNS selective nicotinic receptor ligands hold promise for Parkinson's disease therapy to reduce disease progression, improve symptoms, and/or decrease levodopa‐induced dyskinesias. © 2007 Movement Disorder Society
Url:
- https://api.istex.fr/document/3F9FB8B92C54E896BD388C91549EC7D0FCBE9987/fulltext/pdf
- http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430096
DOI: 10.1002/mds.21900
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000A89
- to stream Istex, to step Curation: Pour aller vers cette notice dans l'étape Curation :000A89
- to stream Istex, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001290
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000202
- to stream Pmc, to step Curation: Pour aller vers cette notice dans l'étape Curation :000202
- to stream Pmc, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000437
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002116
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :002116
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002185
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :002247
- to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :002247
- to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002247
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :003312
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001123
- to stream PascalFrancis, to step Curation: Pour aller vers cette notice dans l'étape Curation :001B96
- to stream PascalFrancis, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001167
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :003775
Links to Exploration step
ISTEX:3F9FB8B92C54E896BD388C91549EC7D0FCBE9987Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Nicotine and Parkinson's disease: Implications for therapy</title>
<author><name sortKey="Quik, Maryka" sort="Quik, Maryka" uniqKey="Quik M" first="Maryka" last="Quik">Maryka Quik</name>
</author>
<author><name sortKey="O Leary, Kathryn" sort="O Leary, Kathryn" uniqKey="O Leary K" first="Kathryn" last="O'Leary">Kathryn O'Leary</name>
</author>
<author><name sortKey="Tanner, Caroline M" sort="Tanner, Caroline M" uniqKey="Tanner C" first="Caroline M." last="Tanner">Caroline M. Tanner</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:3F9FB8B92C54E896BD388C91549EC7D0FCBE9987</idno>
<date when="2008" year="2008">2008</date>
<idno type="doi">10.1002/mds.21900</idno>
<idno type="url">https://api.istex.fr/document/3F9FB8B92C54E896BD388C91549EC7D0FCBE9987/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000A89</idno>
<idno type="wicri:Area/Istex/Curation">000A89</idno>
<idno type="wicri:Area/Istex/Checkpoint">001290</idno>
<idno type="wicri:doubleKey">0885-3185:2008:Quik M:nicotine:and:parkinson</idno>
<idno type="wicri:source">PMC</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430096</idno>
<idno type="RBID">PMC:4430096</idno>
<idno type="wicri:Area/Pmc/Corpus">000202</idno>
<idno type="wicri:Area/Pmc/Curation">000202</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000437</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">002116</idno>
<idno type="wicri:Area/PubMed/Curation">002116</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002185</idno>
<idno type="wicri:Area/Ncbi/Merge">002247</idno>
<idno type="wicri:Area/Ncbi/Curation">002247</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002247</idno>
<idno type="wicri:doubleKey">0885-3185:2008:Quik M:nicotine:and:parkinson</idno>
<idno type="wicri:Area/Main/Merge">003312</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:08-0487362</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001123</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001B96</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001167</idno>
<idno type="wicri:doubleKey">0885-3185:2008:Quik M:nicotine:and:parkinson</idno>
<idno type="wicri:Area/Main/Merge">003775</idno>
<idno type="wicri:Area/Main/Curation">002734</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Nicotine and Parkinson's disease: Implications for therapy</title>
<author><name sortKey="Quik, Maryka" sort="Quik, Maryka" uniqKey="Quik M" first="Maryka" last="Quik">Maryka Quik</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>The Parkinson's Institute, Sunnyvale, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="O Leary, Kathryn" sort="O Leary, Kathryn" uniqKey="O Leary K" first="Kathryn" last="O'Leary">Kathryn O'Leary</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>The Parkinson's Institute, Sunnyvale, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tanner, Caroline M" sort="Tanner, Caroline M" uniqKey="Tanner C" first="Caroline M." last="Tanner">Caroline M. Tanner</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>The Parkinson's Institute, Sunnyvale, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2008-09">2008-09</date>
<biblScope unit="vol">23</biblScope>
<biblScope unit="issue">12</biblScope>
<biblScope unit="page" from="1641">1641</biblScope>
<biblScope unit="page" to="1652">1652</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">3F9FB8B92C54E896BD388C91549EC7D0FCBE9987</idno>
<idno type="DOI">10.1002/mds.21900</idno>
<idno type="ArticleID">MDS21900</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Dyskinesia</term>
<term>Humans</term>
<term>Levodopa</term>
<term>L‐dopa</term>
<term>Nervous system diseases</term>
<term>Nicotine</term>
<term>Nicotine (therapeutic use)</term>
<term>Nicotinic receptor</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (epidemiology)</term>
<term>Parkinson disease</term>
<term>Tobacco smoking</term>
<term>Treatment</term>
<term>dyskinesias</term>
<term>neuroprotection</term>
<term>nicotinic receptors</term>
<term>smoking</term>
<term>striatum</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Nicotine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Humans</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Dyskinésie</term>
<term>Lévodopa</term>
<term>Maladie de Parkinson</term>
<term>Nicotine</term>
<term>Pathologie du système nerveux</term>
<term>Récepteur nicotinique</term>
<term>Tabagisme</term>
<term>Traitement</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Tabagisme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Accumulating evidence suggests that nicotine, a drug that stimulates nicotinic acetylcholine receptors, may be of therapeutic value in Parkinson's disease. Beneficial effects may be several‐fold. One of these is a protective action against nigrostriatal damage. This possibility stems from the results of epidemiological studies that consistently demonstrate an inverse correlation between tobacco use and Parkinson's disease. This reduced incidence of Parkinson's disease has been attributed to the nicotine in tobacco products, at least in part, based on experimental work showing a protective effect of nicotine against toxic insults. Second, several studies suggest a symptomatic effect of nicotine in Parkinson's disease, although effects are small and somewhat variable. Third, recent data in nonhuman primates show that nicotine attenuates levodopa‐induced dyskinesias, a debilitating side effect that develops in the majority of patients on levodopa therapy. Collectively, these observations suggest that nicotine or CNS selective nicotinic receptor ligands hold promise for Parkinson's disease therapy to reduce disease progression, improve symptoms, and/or decrease levodopa‐induced dyskinesias. © 2007 Movement Disorder Society</div>
</front>
</TEI>
<double idat="0885-3185:2008:Quik M:nicotine:and:parkinson"><INIST><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Nicotine and Parkinson's Disease : Implications for Therapy</title>
<author><name sortKey="Quik, Maryka" sort="Quik, Maryka" uniqKey="Quik M" first="Maryka" last="Quik">Maryka Quik</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>The Parkinson's Institute</s1>
<s2>Sunnyvale, California</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="O Leary, Kathryn" sort="O Leary, Kathryn" uniqKey="O Leary K" first="Kathryn" last="O'Leary">Kathryn O'Leary</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>The Parkinson's Institute</s1>
<s2>Sunnyvale, California</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tanner, Caroline M" sort="Tanner, Caroline M" uniqKey="Tanner C" first="Caroline M." last="Tanner">Caroline M. Tanner</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>The Parkinson's Institute</s1>
<s2>Sunnyvale, California</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">08-0487362</idno>
<date when="2008">2008</date>
<idno type="stanalyst">PASCAL 08-0487362 INIST</idno>
<idno type="RBID">Pascal:08-0487362</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001123</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001B96</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001167</idno>
<idno type="wicri:doubleKey">0885-3185:2008:Quik M:nicotine:and:parkinson</idno>
<idno type="wicri:Area/Main/Merge">003775</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Nicotine and Parkinson's Disease : Implications for Therapy</title>
<author><name sortKey="Quik, Maryka" sort="Quik, Maryka" uniqKey="Quik M" first="Maryka" last="Quik">Maryka Quik</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>The Parkinson's Institute</s1>
<s2>Sunnyvale, California</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="O Leary, Kathryn" sort="O Leary, Kathryn" uniqKey="O Leary K" first="Kathryn" last="O'Leary">Kathryn O'Leary</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>The Parkinson's Institute</s1>
<s2>Sunnyvale, California</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tanner, Caroline M" sort="Tanner, Caroline M" uniqKey="Tanner C" first="Caroline M." last="Tanner">Caroline M. Tanner</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>The Parkinson's Institute</s1>
<s2>Sunnyvale, California</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dyskinesia</term>
<term>Levodopa</term>
<term>Nervous system diseases</term>
<term>Nicotine</term>
<term>Nicotinic receptor</term>
<term>Parkinson disease</term>
<term>Tobacco smoking</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Dyskinésie</term>
<term>Tabagisme</term>
<term>Pathologie du système nerveux</term>
<term>Nicotine</term>
<term>Traitement</term>
<term>Lévodopa</term>
<term>Récepteur nicotinique</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Tabagisme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Accumulating evidence suggests that nicotine, a drug that stimulates nicotinic acetylcholine receptors, may be of therapeutic value in Parkinson's disease. Beneficial effects may be several-fold. One of these is a protective action against nigrostriatal damage. This possibility stems from the results of epidemiological studies that consistently demonstrate an inverse correlation between tobacco use and Parkinson's disease. This reduced incidence of Parkinson's disease has been attributed to the nicotine in tobacco products, at least in part, based on experimental work showing a protective effect of nicotine against toxic insults. Second, several studies suggest a symptomatic effect of nicotine in Parkinson's disease, although effects are small and somewhat variable. Third, recent data in nonhuman primates show that nicotine attenuates levodopa-induced dyskinesias, a debilitating side effect that develops in the majority of patients on levodopa therapy. Collectively, these observations suggest that nicotine or CNS selective nicotinic receptor ligands hold promise for Parkinson's disease therapy to reduce disease progression, improve symptoms, and/or decrease levodopa-induced dyskinesias.</div>
</front>
</TEI>
</INIST>
<ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Nicotine and Parkinson's disease: Implications for therapy</title>
<author><name sortKey="Quik, Maryka" sort="Quik, Maryka" uniqKey="Quik M" first="Maryka" last="Quik">Maryka Quik</name>
</author>
<author><name sortKey="O Leary, Kathryn" sort="O Leary, Kathryn" uniqKey="O Leary K" first="Kathryn" last="O'Leary">Kathryn O'Leary</name>
</author>
<author><name sortKey="Tanner, Caroline M" sort="Tanner, Caroline M" uniqKey="Tanner C" first="Caroline M." last="Tanner">Caroline M. Tanner</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:3F9FB8B92C54E896BD388C91549EC7D0FCBE9987</idno>
<date when="2008" year="2008">2008</date>
<idno type="doi">10.1002/mds.21900</idno>
<idno type="url">https://api.istex.fr/document/3F9FB8B92C54E896BD388C91549EC7D0FCBE9987/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000A89</idno>
<idno type="wicri:Area/Istex/Curation">000A89</idno>
<idno type="wicri:Area/Istex/Checkpoint">001290</idno>
<idno type="wicri:doubleKey">0885-3185:2008:Quik M:nicotine:and:parkinson</idno>
<idno type="wicri:source">PMC</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430096</idno>
<idno type="RBID">PMC:4430096</idno>
<idno type="wicri:Area/Pmc/Corpus">000202</idno>
<idno type="wicri:Area/Pmc/Curation">000202</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000437</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">002116</idno>
<idno type="wicri:Area/PubMed/Curation">002116</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002185</idno>
<idno type="wicri:Area/Ncbi/Merge">002247</idno>
<idno type="wicri:Area/Ncbi/Curation">002247</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002247</idno>
<idno type="wicri:doubleKey">0885-3185:2008:Quik M:nicotine:and:parkinson</idno>
<idno type="wicri:Area/Main/Merge">003312</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Nicotine and Parkinson's disease: Implications for therapy</title>
<author><name sortKey="Quik, Maryka" sort="Quik, Maryka" uniqKey="Quik M" first="Maryka" last="Quik">Maryka Quik</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>The Parkinson's Institute, Sunnyvale, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="O Leary, Kathryn" sort="O Leary, Kathryn" uniqKey="O Leary K" first="Kathryn" last="O'Leary">Kathryn O'Leary</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>The Parkinson's Institute, Sunnyvale, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tanner, Caroline M" sort="Tanner, Caroline M" uniqKey="Tanner C" first="Caroline M." last="Tanner">Caroline M. Tanner</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>The Parkinson's Institute, Sunnyvale, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2008-09">2008-09</date>
<biblScope unit="vol">23</biblScope>
<biblScope unit="issue">12</biblScope>
<biblScope unit="page" from="1641">1641</biblScope>
<biblScope unit="page" to="1652">1652</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">3F9FB8B92C54E896BD388C91549EC7D0FCBE9987</idno>
<idno type="DOI">10.1002/mds.21900</idno>
<idno type="ArticleID">MDS21900</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Humans</term>
<term>L‐dopa</term>
<term>Nicotine (therapeutic use)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (epidemiology)</term>
<term>dyskinesias</term>
<term>neuroprotection</term>
<term>nicotinic receptors</term>
<term>smoking</term>
<term>striatum</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Nicotine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Humans</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Accumulating evidence suggests that nicotine, a drug that stimulates nicotinic acetylcholine receptors, may be of therapeutic value in Parkinson's disease. Beneficial effects may be several‐fold. One of these is a protective action against nigrostriatal damage. This possibility stems from the results of epidemiological studies that consistently demonstrate an inverse correlation between tobacco use and Parkinson's disease. This reduced incidence of Parkinson's disease has been attributed to the nicotine in tobacco products, at least in part, based on experimental work showing a protective effect of nicotine against toxic insults. Second, several studies suggest a symptomatic effect of nicotine in Parkinson's disease, although effects are small and somewhat variable. Third, recent data in nonhuman primates show that nicotine attenuates levodopa‐induced dyskinesias, a debilitating side effect that develops in the majority of patients on levodopa therapy. Collectively, these observations suggest that nicotine or CNS selective nicotinic receptor ligands hold promise for Parkinson's disease therapy to reduce disease progression, improve symptoms, and/or decrease levodopa‐induced dyskinesias. © 2007 Movement Disorder Society</div>
</front>
</TEI>
</ISTEX>
</double>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002734 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 002734 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Curation |type= RBID |clé= ISTEX:3F9FB8B92C54E896BD388C91549EC7D0FCBE9987 |texte= Nicotine and Parkinson's disease: Implications for therapy }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |